Tonix Pharmaceuticals Files 8-K
Ticker: TNXP · Form: 8-K · Filed: Mar 10, 2025 · CIK: 1430306
Sentiment: neutral
Topics: corporate-filing, financial-reporting
Related Tickers: TNXP
TL;DR
TNXP filed an 8-K on 3/10/25 covering financial statements and other events.
AI Summary
Tonix Pharmaceuticals Holding Corp. filed an 8-K on March 10, 2025, reporting on various events. The filing includes information on financial statements and exhibits, as well as other events and a Regulation FD disclosure. The company, formerly known as Tamandare Explorations Inc., is incorporated in Nevada and headquartered in Chatham, New Jersey.
Why It Matters
This 8-K filing provides updates on Tonix Pharmaceuticals' corporate activities and financial reporting, which are important for investors to monitor the company's status and compliance.
Risk Assessment
Risk Level: low — This filing is a routine corporate disclosure and does not appear to contain significant new risks or material adverse information.
Key Players & Entities
- Tonix Pharmaceuticals Holding Corp. (company) — Registrant
- March 10, 2025 (date) — Filing Date
- Tamandare Explorations Inc. (company) — Former Company Name
- Nevada (jurisdiction) — State of Incorporation
- Chatham, New Jersey (location) — Principal Executive Offices
FAQ
What is the primary purpose of this 8-K filing?
This 8-K filing serves as a current report for Tonix Pharmaceuticals Holding Corp., covering items such as Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits.
When was this 8-K report filed?
The report was filed on March 10, 2025.
What was Tonix Pharmaceuticals Holding Corp. previously named?
The company was formerly known as Tamandare Explorations Inc.
In which state is Tonix Pharmaceuticals Holding Corp. incorporated?
The company is incorporated in Nevada.
What is the address of Tonix Pharmaceuticals Holding Corp.'s principal executive offices?
The principal executive offices are located at 26 Main Street, Suite 101, Chatham, New Jersey 07928.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on March 10, 2025 regarding Tonix Pharmaceuticals Holding Corp. (TNXP).